Livongo for Hypertension Demonstrates BP Benefit at 4 and 12 Weeks
Livongo announced results from a 12-week study evaluating the impact of its Livongo for Hypertension program. Full results from the study will be presented at the AHA conference on November 16, 2019. Below, FENIX provides brief thoughts on the new Livongo data.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.